Purple Biotech LTD. key statistics and ratios

In fiscal 2020, Purple Biotech LTD. had return on equity of 62.4%, an operating margin of -1261.2%, debt equal to 0.0% of equity and a current ratio of 19.14. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Purple Biotech LTD.: financial ratios, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Operating margin	<−999%	−782.6%	−715.6%	<−999%
Net margin	>999%	520.0%	585.0%	>999%
Free-cash-flow margin	<−999%	−849.6%	−197.9%	154.9%
Return on equity	164.4%	58.0%	55.9%	62.4%
Return on assets	85.9%	36.0%	39.7%	56.8%
Asset turnover	0.01	0.07	0.07	0.02
Current ratio	2.01	2.57	2.34	19.14
Debt to equity	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	—	n/m	n/m
R&D as % of revenue	>999%	526.8%	227.8%	723.8%
Capital spending as % of revenue	13.0%	1.6%	1.1%	15.6%
Free cash flow ÷ net income	−71.0%	−163.4%	−33.8%	5.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 1 checks passed · December 31, 2025

What it owns · $18m

Short-term assets $10mLonger-term assets $8m

What it owes, and who funded it · $17m

Short-term liabilities $8mShareholders' equity $10m

Short-term assets cover short-term liabilities $10m of assets due within a year against $8m of liabilities due within a year.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Purple Biotech LTD.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Purple Biotech LTD.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Purple Biotech LTD.